BSB the location of the editing offices of the journal are irrelevant. All that matters is it's standing in the academic/medical world and the lancet and the NEJM are the top dogs for clinical research. The lancet will make their decisions totally independently of the MHRA. Anyway like Vubru was saying...not meeting those orginal endpoints doesn't make it impossible to publish there especially if they can show data to explain why those endpoints weren't met (in a journal they can be more 'exploratory' with the analysis unlike when formally asking for approval)...just that bit harder.
Market Data 
Markets 
AI
